Clonogenic assays revealed that patient-specific TP53 mutations are present in the vast majority of HSC-derived colonies (median, 97%; range, 45 to 100%), with only a paucity of cooperating mutations in known cancer genes, as seen above. Here, TP53 is linked to cancer.